Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05010031 · ClinicalTrials.gov registry record · Phase 2

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

A Phase 2 study of Metastatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
7
Study locations

NCT05010031: Recruiting Phase 2 study of Metastatic Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT05010031 is a Phase 2 study of Metastatic Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05010031, a Phase 2 study of Metastatic Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
7
Study locations

Study Summary

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

Primary Outcome

Defined as (i) radiographic progression or (ii) re-irradiation to the treated site. If PET is performed, radiographic criteria will be evaluated per PERCIST

Conditions Studied

Interventions

  • RADIATION Palliative radiotherapy

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack (All protocol activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All protocol activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (All protocol activities) - Montvale

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-08-11
Est. Completion 2027-08
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT05010031 shows while recruiting

NCT05010031 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Palliative radiotherapy is the first listed.

NCT05010031 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT05010031 about?

NCT05010031 is a clinical study titled "A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change". This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

What is the current status of trial NCT05010031?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-08-11. Estimated completion is 2027-08.

What conditions does trial NCT05010031 study?

This clinical trial studies the following conditions: Metastatic Cancer.

What interventions are being tested in trial NCT05010031?

The interventions under investigation include: Palliative radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT05010031?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05010031 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05010031's enrollment target sits among peer trials

40 67th of 109 higher than 38 of 109 other Metastatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05010031, the US trial registry maintained by the National Library of Medicine. NCT05010031 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.